Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

EEstrella Immunopharma, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
E

Estrella Immunopharma, Inc.

$0.49Close · Sep 22, 2026
  • Overview
  • Financial statements
  • Metrics
    • Revenue & profit
    • Revenue by segment
    • Launches
    • Revenue concentration
    • Margins
    • Contracted revenue
    • Off-balance-sheet commitments
    • Cash flow
    • Cash & debt
    • Earnings per share
    • P/E ratio
    • Share count & dilution
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • Insider Transactions
Loading financial graphs

Metrics

Revenue & profit
Revenue by segment
Margins
Contracted revenue
Cash flow
Cash & debt
Earnings per share
Share count & dilution

Metrics

Compare cash generated by the business, spending on long-lived assets, and what remains afterward.Formula: Free cash flow = operating cash flow − capital expenditures
$
20252022202320242025-15M-10M-5M0
      Latest period 2025. Operating cash flow -1.8M.
      Operating cash flowCapexFree cash flow
      Compare the company’s cash cushion with its borrowings. Negative net cash means debt is greater than cash.Formula: Net cash = cash − debt
      20262022202320242025202605M10M15M20M
          Latest period 2026. Cash 100K.
          CashDebtNet cash
          Profit for each share over the trailing 12 months, adjusted for stock splits.Formula: Earnings available to common shareholders ÷ weighted-average shares
          $/shareUsing split history cached 2026-09-23; assuming no new splits
          common_earnings_missingMissingcommon_earnings_missingMissing20252022202320242025-1.50-1.00-0.500.000.501.00
          • FY 2023: common earnings missing
          • FY 2024: common earnings missing
          • Earnings period 2022-01-01 to 2022-12-31. Shares as of 2022-12-31: 1,419,700 source shares.
          • Earnings period 2022-07-01 to 2023-06-30. Shares as of 2023-06-30: unavailable source shares.
          • Earnings period 2023-07-01 to 2024-06-30. Shares as of 2024-06-30: unavailable source shares.
          • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2026-03-12: 42,665,228 source shares. Uses later-dated shares from the same quarterly filing.
          Latest period FY 2025. EPS (TTM) -0.31.
          EPS (TTM)
          How much investors pay for each dollar of the company’s yearly earnings. It is not useful when the company has no profit.Formula: Share price ÷ trailing 12-month EPS
          Using split history cached 2026-09-23; assuming no new splits
          common earnings missingMissingcommon earnings missingMissing20252022202320242025-15x-10x-5x0x
          • FY 2023: common earnings missing
          • FY 2024: common earnings missing
          • Earnings period 2022-01-01 to 2022-12-31. Shares as of 2022-12-31: 1,419,700 source shares. Nearby weekly price on 2022-12-30.
          • Earnings period 2022-07-01 to 2023-06-30. Shares as of 2023-06-30: unavailable source shares.
          • Earnings period 2023-07-01 to 2024-06-30. Shares as of 2024-06-30: unavailable source shares.
          • Earnings period 2025-01-01 to 2025-12-31. Shares as of 2026-03-12: 42,665,228 source shares. Uses later-dated shares from the same quarterly filing. Nearby weekly price on 2026-03-13.
          Latest period FY 2025. P/E ratio -4.1x.
          P/E ratio
          See how the number of shares changes over time. More shares can mean each existing share owns a smaller slice of the company.Formula: Outstanding shares = issued shares − treasury shares Share-count growth = (current shares ÷ previous shares − 1) × 100%
          Stock split history may be out of date.
          202620222023202420252026010M20M30M40M
              Latest period Shares as of 2026-08-11 (quarter ended 2026-06-30). Shares outstanding 43.5M. Class detail unavailable 43.5M.
              Class detail unavailable